Drugs / Nolasiban
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02326142 | Mar 2015 → Oct 2016 | — | ObsEva SA | Terminated | No outcome recorded |
| Phase 2 | NCT02310802 | Nov 2014 → Nov 2015 | female infertility | ObsEva SA | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03758885 | Jan → Nov 2019 | infertility disorder | ObsEva SA | Completed | No outcome recorded |
| Phase 3 | NCT03081208 | Mar 2017 → Mar 2018 | infertility disorder | ObsEva SA | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nolasiban | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03758885 ↗ |
| Known as | Erlosiban | ChEMBL registry synonym — accepted as the source's own label CHEMBL1254025 ↗ |
| Known as | OBE001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02326142 ↗ |
| Action | Inhibit | “the oxytocin receptor antagonist OBE001” NCT02310802 ↗1“Oxytocin receptor antagonist” CHEMBL1254025 ↗ |
| Modality | Small molecule | — CHEMBL1254025 ↗ |
| Route | Oral | “single oral administration” NCT02310802 ↗ |
| Target | OXTR | “Oxytocin receptor antagonist” CHEMBL1254025 ↗ |